My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novartis AG Common Stock (NY:NVS)

164.70 +2.03 (+1.25%)

Official Closing Price Updated: 4:10 PM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

55 56 Next >

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗

December 13, 2024

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

Via Benzinga

Why the dividend investor may take a look at NYSE:NVS. ↗

December 13, 2024

Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock.

Via Chartmill

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗

December 10, 2024

The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.

Via Investor's Business Daily

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder ↗

December 06, 2024

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

Via Benzinga

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst ↗

December 03, 2024

Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients.

Via Benzinga

2 Dividend Stocks to Buy and Hold Forever ↗

December 01, 2024

Via The Motley Fool

Exploring NYSE:NVS's dividend characteristics. ↗

November 22, 2024

Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing?

Via Chartmill

Is NYSE:NVS suited for dividend investing? ↗

November 01, 2024

Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS).

Via Chartmill

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program ↗

December 02, 2024

PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties.

Via Benzinga

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone ↗

December 02, 2024

The deal focuses on the company's treatment for Huntington's disease.

Via Investor's Business Daily

Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline ↗

November 21, 2024

Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, and a promising innovation pipeline.

Via Benzinga

Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details ↗

November 12, 2024

Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3...

Via Benzinga

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

Novartis Reports Q3 Momentum, But Shares Lose Support ↗

October 29, 2024

Novartis stock slipped Tuesday, despite a solid Q3 performance and an upgraded outlook.

Via Investor's Business Daily

Looking Into Novartis's Recent Short Interest ↗

October 14, 2024

Via Benzinga

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗

October 30, 2024

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

Via Benzinga

Novartis Ag (NVS) Q3 2024 Earnings Call Transcript ↗

October 29, 2024

NVS earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Why NYSE:NVS is a Top Pick for Dividend Investors. ↗

October 09, 2024

Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics.

Via Chartmill

Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook ↗

October 29, 2024

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Via Benzinga

Topics Earnings

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis ↗

October 28, 2024

The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases.

Via Investor's Business Daily

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”

October 28, 2024

Via AB Newswire

Topics Artificial Intelligence

Why Is Monte Rosa Therapeutics Stock Surging On Monday? ↗

October 28, 2024

Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions.

Via Benzinga

3 Absurdly Cheap Stocks That Pay High Dividends ↗

October 24, 2024

These stocks are trading at less than 15 times their expected future profits.

Via The Motley Fool

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗

October 18, 2024

Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...

Via Benzinga

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer ↗

October 18, 2024

Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European...

Via Benzinga

1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move ↗

October 17, 2024

Novartis is taking a more calculated and strategic approach to its growth.

Via The Motley Fool

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗

October 16, 2024

William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales...

Via Benzinga

2 Magnificent Dividend Stocks to Buy and Hold Forever ↗

October 14, 2024

These companies have compelling track records.

Via The Motley Fool

Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm ↗

October 10, 2024

OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.